Prelude Therapeutics is a clinical-stage precision oncology company developing small-molecule medicines aimed at high-unmet-need cancers. Its programs focus on novel targets and mechanisms intended to treat molecularly defined patient populations rather than broad, non-selective chemotherapies. Based in Wilmington, Delaware, the company generates limited revenue while advancing candidates through clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -31.2 | — |
| Q3 2025 | 6.5 | — | -19.7 | — |
| Q4 2025 | 5.6 | — | -16.5 | — |
| Q1 2026 | 4.6 | — | -10.4 | — |
| Q2 2026 | 5.7 | — | -13.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: TRG Latin America Acquisitions Corp. (TRGS), Omega Flex, Inc. (OFLX), Vendome Acquisition Corporation I (VNME), EyePoint, Inc. (EYPT), Upstream Bio, Inc. (UPB), StablecoinX Inc. (USDE)